Noesis Capital Mangement Corp Purchases 27,938 Shares of Stryker Corporation $SYK

Noesis Capital Mangement Corp raised its position in Stryker Corporation (NYSE:SYK) by 36.3% in the third quarter, HoldingsChannel reports. The fund owned 104,945 shares of the medical technology company’s stock after purchasing an additional 27,938 shares during the quarter. Stryker makes up approximately 3.4% of Noesis Capital Mangement Corp’s holdings, making the stock its 8th largest holding. Noesis Capital Mangement Corp’s holdings in Stryker were worth $28,901,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Apollon Wealth Management LLC lifted its holdings in shares of Stryker by 21.2% in the 3rd quarter. Apollon Wealth Management LLC now owns 11,156 shares of the medical technology company’s stock worth $3,072,000 after purchasing an additional 1,950 shares in the last quarter. Kingswood Wealth Advisors LLC increased its stake in Stryker by 2.5% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 2,285 shares of the medical technology company’s stock valued at $629,000 after purchasing an additional 56 shares in the last quarter. Provident Investment Management Inc. raised its holdings in Stryker by 2.1% during the third quarter. Provident Investment Management Inc. now owns 2,186 shares of the medical technology company’s stock worth $602,000 after buying an additional 46 shares during the last quarter. Valley National Advisers Inc. raised its holdings in Stryker by 48.3% during the third quarter. Valley National Advisers Inc. now owns 8,442 shares of the medical technology company’s stock worth $2,325,000 after buying an additional 2,748 shares during the last quarter. Finally, Radnor Capital Management LLC lifted its stake in shares of Stryker by 2.6% in the third quarter. Radnor Capital Management LLC now owns 13,730 shares of the medical technology company’s stock valued at $3,781,000 after buying an additional 342 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on SYK shares. Sanford C. Bernstein reissued a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Citizens Jmp decreased their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. Canaccord Genuity Group lowered their price objective on Stryker from $400.00 to $385.00 and set a “buy” rating for the company in a research note on Friday, September 18th. BTIG Research dropped their target price on Stryker from $358.00 to $316.00 and set a “buy” rating on the stock in a report on Monday, October 12th. Finally, TD Cowen cut their target price on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $369.00.

Stryker Stock Down 0.2%

Stryker stock opened at $306.50 on Tuesday. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm’s 50-day simple moving average is $295.95 and its 200 day simple moving average is $326.09. The stock has a market cap of $117.56 billion, a PE ratio of 31.76, a price-to-earnings-growth ratio of 1.98 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the business posted $3.13 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling

In other Stryker news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.